CellTosg2Sequence: A Unified Text-Omics-Signaling-Graph Large Language Model for Single-Cell Analysis

Read the full article See related articles

Discuss this preprint

Start a discussion What are Sciety discussions?

Listed in

This article is not in any list yet, why not save it to one of your lists.
Log in to save this article

Abstract

In single-cell (sc)-based scientific discovery, text-formatted biomedical prior knowledge and signaling graphs are essential for annotating and interpreting numeric sc-omics data and for generating novel testable hypotheses. A major limitation of existing single-cell large language models (scLLMs) is that they rely on numeric expression data with gene names as the only textual signal, while comprehensive biomedical priors — cellular localization, gene function, disease associations, and signaling interaction patterns — remain absent from the model input. We introduce CellTosg2Sequence , a textual-prior- and signaling-graph-augmented cell-omics-sentence language model.

A lightweight heterogeneous graph encoder maps a curated 62,507-node biomedical knowledge graph (KG) into compact virtual tokens that are prepended to each cell sentence, allowing the language model to condition on biological structure with minimal sequence-length overhead. We train CellTosg2Sequence with a three-stage objective: Stage I anchors the KG channel under autoregressive language-model pretraining, leveraging Qwen2.5-32B’s own language reasoning for rapid KG alignment; Stage II aligns labels via supervised fine-tuning with KG-anchored InfoNCE; Stage III applies Group Relative Policy Optimization (GRPO) with an ontology-hierarchy reward, enabling free-generation cell-type prediction that generalizes beyond the closed training vocabulary.

Across multiple benchmarks and ablation experiments, CellTosg2Sequence outperforms strong baselines. All results are achieved with lightweight LoRA training and a single unified checkpoint.

Data ethics

This work uses publicly available single-cell datasets from the Human Cell Atlas ( https://www.humancellatlas.org ) and the Tahoe-100M consortium. All HCA constituent studies were collected under appropriate donor consent and institutional oversight as described in their original publications; we perform computational re-analysis only and introduce no new human subjects data. HCA data access follows the HCA Data Portal terms of use. No new patient data are collected in this study; no additional IRB approval is required for this secondary computational analysis.

Article activity feed